



(11) **EP 1 741 782 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A2)
INID code(s) 71

(51) Int Cl.:

C12N 15/12 (2006.01) **C07K 14/47** (2006.01)
A61K 39/00 (2006.01) **A61K 38/17** (2006.01)
C12N 15/863 (2006.01) **C12N 15/861** (2006.01)
A61K 31/7088 (2006.01) **A61K 48/00** (2006.01)

(48) Corrigendum issued on:

07.03.2007 Bulletin 2007/10

(43) Date of publication:

10.01.2007 Bulletin 2007/02

(21) Application number: **06021369.1**

(22) Date of filing: **07.05.2001**

(84) Designated Contracting States:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

(30) Priority: **10.05.2000 US 202970 P**

11.05.2000 US 203578 P

20.10.2000 US 242388 P

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

01931269.3 / 1 282 702

(71) Applicants:

- **Sanofi Pasteur Limited**
Toronto, Ontario M2R 3T4 (CA)
- **LUDWIG INSTITUTE FOR CANCER RESEARCH**
1200 Brussels (BE)

(72) Inventors:

- **Berinstein, Neil**
Toronto, Ontario M5P 1V1 (CA)
- **Tartaglia, Jim**
Aurora, Ontario L4G 6R6 (CA)

- **Tine, John A.**
Scotia, NY 12302 (US)
- **Moingeon, Philippe**
F-69480 Pommiers (FR)
- **Boon-Falleur, Thierry,**
Ludwig Institute
B-1200 Brussels (BE)
- **Van Der Bruggen, Pierre,**
Ludwig Institute
B-1200 Brussels (BE)

(74) Representative: **Cole, William Gwyn et al**


HLBBshaw
Merlin House
Falconry Court
Baker's Lane
Epping, Essex CM16 5DQ (GB)

Remarks:

This application was filed on 12 - 10 - 2006 as a divisional application to the application mentioned under INID code 62.

(54) **Immunogenic polypeptides encoded by MAGE minigenes and uses thereof**

(57) The invention discloses immunogenic polypeptides comprising several MAGE-specific antigen epitopes selected from different (i.e. discrete) members of the MAGE protein family, nucleic acids coding therefor, recombinant viruses and/or cells comprising said nucleic acids, and compositions thereof. Methods for eliciting or inducing MAGE-specific immune responses utilizing the aforementioned immunogenic agents are also disclosed.



EP 1 741 782 A8